Filing Details

Accession Number:
0001209191-18-057429
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-06 17:00:47
Reporting Period:
2018-11-02
Accepted Time:
2018-11-06 17:00:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1581280 Twist Bioscience Corp TWST () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219039 Keith Crandell 8755 W. Higgins Road, Suite 1025
Chicago IL 60631
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-11-02 1,182,645 $0.00 1,182,645 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-11-02 718,275 $0.00 1,900,920 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-11-02 266,776 $0.00 2,167,696 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-11-02 224,726 $0.00 2,392,422 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-11-02 15,000 $14.00 2,407,422 No 4 P Indirect See footnotes
Common Stock Acquisiton 2018-11-02 894,146 $0.00 894,146 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-11-02 60,000 $14.00 954,146 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2018-11-02 1,182,645 $0.00 1,182,645 $0.00
Common Stock Series B Preferred Stock Disposition 2018-11-02 718,275 $0.00 718,275 $0.00
Common Stock Series C Preferred Stock Disposition 2018-11-02 266,776 $0.00 266,776 $0.00
Common Stock Series D Preferred Stock Disposition 2018-11-02 224,726 $0.00 224,726 $0.00
Common Stock Series D Preferred Stock Disposition 2018-11-02 894,146 $0.00 894,146 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 0 Direct
Footnotes
  1. Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
  2. The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  3. Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  4. Reflects shares purchased in the Issuer's initial public offering.
  5. The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  6. The expiration date is not relevant to the conversion of these securities.